



PHA 2011 (3167/2Z/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1614
Serial No. 09/857,876
Filed October 5, 2001
Confirmation No. 2805
For METHOD OF USING A MATRIX METALLOPROTEINASE INHIBITOR AND
RADIATION THERAPY AS COMBINATION THERAPY IN THE TREATMENT OF
NEOPLASIA
Examiner Cybille Delacroix-Muirhei

January 21, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

Please note that Applicants make no representation as to the accuracy or completeness of the translation of Reference No. 57 submitted herewith.


In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

01/26/2004 NKCHA1 00000012 09857876

* A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

* Also enclosed is Applicants' executed Power of Attorney.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/msc
*Enclosures

Express Mail Label No. EV 324379087 US

PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/857,876
				Filing Date	October 5, 2001
				Confirmation Number	2805
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1614
Examiner Name	Cybillie Delacroix-Muirhei				
Sheet	1	of	1	Attorney Docket No.	PHA 2011 (3167/2Z/US)

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	53.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998	
	54.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
	55.	BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumori, 1998, pp. 45-47, Vol. 84, No. 1					
	56.	COMIS, R.L., et al., Small-Cell Lung Cancer: A Perspective on the Past and a Preview of the Future, Oncology, Jan. 1998, pp. 44-50, Vol. 12, Suppl. No. 2					
	57.	MULLER-BOHN, T., et al., (1997) Deutsche Apotheker Zeitung, pp. 54-55, Vol. 137, No. 41					✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.